Edwards Lifesciences' EVOQUE Data Shows Lower Two-Year Mortality

Edgen Stock

·Mar 30 2026, 14:23

Share to

Share to

Copy link

Key Takeaways

Edwards Lifesciences presented positive two-year clinical data for its EVOQUE heart valve system, demonstrating improved patient outcomes and lower mortality. The results, shared on March 30, 2026, strengthen the case for regulatory approval and could solidify the company's leadership in the transcatheter valve market.

New Data: Edwards Lifesciences unveiled two-year results from its TRISCEND II trial for the EVOQUE transcatheter tricuspid valve replacement (TTVR) system.
Patient Outcomes: The study showed significant and sustained patient benefits, including a lower mortality rate over a two-year period.
Market Impact: The positive long-term data enhances the product's prospects for regulatory approval and wider market adoption, potentially boosting revenue for Edwards Lifesciences (NYSE: EW).

EVOQUE System Data Shows Lower Mortality Over Two Years

Edwards Lifesciences presented favorable two-year data for its EVOQUE transcatheter tricuspid valve replacement (TTVR) system on March 30, 2026. Unveiled at the American College of Cardiology's Annual Scientific Session, the findings from the TRISCEND II pivotal trial demonstrate significant and sustained benefits for patients, most notably a lower mortality rate. These results extend and reinforce positive initial data previously shared at the European Society of Cardiology Congress in 2025, providing a longer-term view of the device's efficacy and safety.

Positive Trial Results Bolster Market Leadership Case

The strong, long-term performance data significantly strengthens the EVOQUE system's profile as it moves toward full regulatory approval and broader commercialization. For Edwards Lifesciences (NYSE: EW), these results could secure a leading position in the emerging market for transcatheter tricuspid valve therapies. The trial's success comes as medical societies begin to establish formal requirements for these procedures, signaling a maturing market ready for validated solutions. This positions the company to capture significant revenue and expand its competitive advantage in the structural heart device sector.